Table 4 Functions and canonical pathways as differentially expressed down-regulated genes in ob/ob vs. WT, with no significant changes in POKO vs. WT mice
Top Bio Functions | ||
|---|---|---|
Name | p-value | # Molecules |
Diseases and Disorders | ||
Dermatological Diseases and Conditions | 3.01E-05 - 4.21E-02 | 37 |
Genetic Disorder | 3.01E-05 - 4.21E-02 | 91 |
Cancer | 9.80E-05 - 4.21E-02 | 170 |
Developmental Disorder | 6.95E-04 - 4.21E-02 | 11 |
Gastrointestinal Disease | 1.48E-03 - 4.21E-02 | 71 |
Molecular and Cellular Functions | ||
Lipid Metabolism | 4.46E-07 - 4.21E-02 | 50 |
Small Molecule Biochemistry | 4.46E-07 - 4.21E-02 | 71 |
Vitamin and Mineral Metabolism | 4.46E-07 - 4.21E-02 | 23 |
Cell-To-Cell Signaling and Interaction | 1.48E-04 - 4.21E-02 | 63 |
Cellular Assembly and Organization | 1.48E-04 - 4.21E-02 | 46 |
Physiological System Development and Function | ||
Tumor Morphology | 9.80E-05 - 4.21E-02 | 22 |
Hair and Skin Development and Function | 1.37E-03 - 4.21E-02 | 26 |
Organ Development | 1.37E-03 - 4.18E-02 | 35 |
Digestive System Development and Function | 1.50E-03 - 1.95E-02 | 11 |
Organismal Development | 1.50E-03 - 4.18E-02 | 26 |
Top Canonical Pathways | ||
Name | p-value | Ratio |
Biosynthesis of Steroids | 1.96E-04 | 7/128(0.055) |
HER-2 Signaling in Breast Cancer | 3.41E-03 | 9/79 (0.114) |
Tight Junction Signaling | 9.59E-03 | 13/167 (0.078) |
Fatty Acid Biosynthesis | 1.23E-02 | 3/51 (0.059) |
ERK5 Signaling | 1.26E-02 | 7/71 (0.099) |